ArticleCurrent microbiology2025
Protection of Ducks Against Highly Pathogenic H5Nx Avian Influenza Viruses by HA Cleavage Site Peptide Vaccine.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Enhanced induction of inflammatory cytokines in human lung cells infected with highly pathogenic recent H5N1/2024 avian influenza virus.Archives of virology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Highly pathogenic H5Nx avian influenza viruses are endemic in animals in many countries. These viruses cause the severe diseases in chickens, but they cause much milder diseases in ducks. The vaccination is one of the tools to prevent the infections of ducks by highly pathogenic H5Nx avian influenza viruses. Here, we studied the efficacy of oil-adjuvanted H5 cleavage peptide vaccine in ducks. The vaccinated ducks challenged with H5N6 and H5N8 avian influenza viruses were protected without viral detection in the tracheal and cloacal swabs. The protective immunity in the immunized ducks lasted until 16 weeks post-vaccination. Our results suggest that H5 cleavage site peptide vaccine can be one of the candidate vaccines to provide the protective immunity to ducks against H5Nx avian influenza viruses.Please confirm if the author names are presented accurately and in the correct sequence. Also, kindly confirm the details in the metadata are correct.Yes, It's correct.Please check and confirm that the authors and their respective affiliations have been correctly identified and amend if necessary.Yes, It's correct.Please confirm the section headings are correctly identified.Yes, It's correct.Kindly check and confirm the edit made in the title.Yes, It's OK. LE: Kindly check and confirm whether the edit made in the article title is appropriate.Yes, It's OK.
Indexed as
Identifiers
40133682What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.